Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity and Common Stock Purchase Warrants (Details Narrative)

v3.19.3
Stockholders' Equity and Common Stock Purchase Warrants (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Nov. 12, 2019
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Common stock, shares authorized   100,000,000   100,000,000   100,000,000
Common stock, par value per share   $ 0.001   $ 0.001   $ 0.001
Common stock, shares issued   36,556,178   36,556,178   27,142,979
Common stock, shares outstanding   36,556,178   36,556,178   27,142,979
Number of shares issued       5,480,000    
Gross proceeds from issuance of common stock       $ 5,480,000  
Placement agent fees and legal fees       $ 101,098    
Senior secured convertible note conversion, shares issued       3,850,427    
Debt issuance date       Dec. 27, 2018    
Number of stock issed under Employee Stock Purchase Plan       82,772    
Stock-based compensation   $ 330,233 $ 324,473 $ 1,177,282 899,649  
Lucid Diagnostics Inc [Member]            
Common stock, shares issued   10,000,000   10,000,000   10,000,000
Common stock, shares outstanding   10,000,000   10,000,000   10,000,000
Majority ownership interest percentage   81.875%   81.875%   81.875%
Common Stock [Member]            
Number of shares issued       5,480,000    
Noncontrolling Interest [Member] | Lucid Diagnostics Inc [Member]            
Majority ownership interest percentage   18.125%   18.125%   18.125%
Subsequent Event [Member]            
Senior secured convertible note conversion, shares issued 202,950          
Placement Agency Agreement [Member]            
Number of shares issued       530,000    
Management Services Agreement [Member]            
Stock-based compensation       $ 600,000 $ 90,000  
Individual Investors [Member]            
Number of shares issued       4,950,000